CGM
BIIB icon

Capital Growth Management’s Biogen BIIB Stock Holding History

Capital Growth Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-80,000
Closed -$26.5M – 60
2014
Q3 		$26.5M Buy
+80,000
New +$26.4M 0.75% 37
2014
Q2 		– Sell
-116,000
Closed -$35.5M – 69
2014
Q1 		$35.5M Buy
+116,000
New +$36.8M 0.95% 31
2013
Q3 		– Sell
-45,000
Closed -$9.68M – 67
2013
Q2 		$9.68M Buy
+45,000
New +$9.62M 0.26% 57

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital Growth Management's BIIB Position: Q4 2014 in Review

Capital Growth Management sold out of Biogen (BIIB) in Q4 2014, closing a stake of 80,000 shares — an estimated $26.5M sold.

Capital Growth Management first reported a position in BIIB in Q2 2013 and held it in 3 quarters. The position peaked at $35.5M in Q1 2014. 885 funds tracked by Wall St. Rank hold BIIB as of Q4 2014.

  • Capital Growth Management reported no remaining Biogen position as of Q4 2014 after selling out during the quarter.
  • Capital Growth Management sold 80,000 Biogen shares in Q4 2014, an estimated $26.5M.
  • Capital Growth Management first reported a position in Biogen in Q2 2013 and held it in 3 quarters.
  • Capital Growth Management's Biogen position peaked at $35.5M in Q1 2014.
  • 885 funds tracked by Wall St. Rank held Biogen as of Q4 2014.

Based on Capital Growth Management's 13F filing for Q4 2014, filed 13 Feb 2015.